ES-481

DRUG3 trials

Sponsors

ES Therapeutics Australia Pty Ltd

Conditions

Drug Resistant EpilepsyEpilepsy; SeizureTremor, Essential

Phase 2

Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy

ES Therapeutics Australia Pty LtdDrug Resistant Epilepsy

Start: 2020-10-30End: 2023-12-31Target: 24Updated: 2023-03-02

ES-481 for Uncontrolled Glioma-Associated Epilepsy and Assessment for Potential Anti-Tumorigenic Effect in Patients With Isocitrate Dehydrogenase 1 (IDH1) Mutant Tumors

WithdrawnNCT04737174

ES Therapeutics Australia Pty LtdEpilepsy; Seizure

Start: 2021-03-25End: 2022-04-30Updated: 2022-04-06

Efficacy, Safety, and Pharmacokinetics of ES-481 in Adult Patients With Essential Tremors

ES Therapeutics Australia Pty LtdTremor, Essential

Start: 2021-11-21End: 2023-12-31Target: 24Updated: 2023-03-02